Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer

Abstract 

Non-muscle-invasive bladder cancer (NMIBC) presents a significant clinical challenge due to its high rate of recurrence and potential for progression. The current standard of care, which involves transurethral resection followed by intravesical chemotherapy or immunotherapy (most commonly BCG), is limited by poor drug penetration into the bladder wall and suboptimal retention times, leading to a high rate of treatment failure. This review article explores the transformative landscape of device-based drug delivery bladder cancer therapies, which are designed to overcome these fundamental limitations. We provide a comprehensive overview of the mechanisms, clinical data, and future potential of three key technologies: electromotive drug administration (EMDA), chemohyperthermia, and novel sustained-release devices. EMDA utilizes an electrical current to enhance the penetration of agents like mitomycin C, demonstrating superior recurrence-free survival compared to passive diffusion. Similarly, chemohyperthermia, which combines chemotherapy with controlled heating of the bladder, significantly boosts drug cytotoxicity and offers a potent bladder-sparing option. The most recent breakthrough lies in the development of a sustained-release gemcitabine bladder device, such as the TAR-200, which provides continuous drug exposure over weeks, yielding unprecedented complete response rates in patients with BCG-unresponsive NMIBC. By enhancing drug delivery and dwell time, these device-assisted therapies are redefining the treatment paradigm for NMIBC recurrence, offering new hope for durable disease control and improving the clinical outcomes for a high-risk patient population.

Introduction 

Bladder cancer stands as a major public health concern in the United States, ranking among the most common malignancies. While most patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC), which is confined to the inner lining of the bladder, this seemingly benign classification belies a high-stakes clinical reality. NMIBC is a heterogeneous and highly recurrent disease, with a staggering 50-70% of patients experiencing a relapse within five years of initial treatment. This relentless cycle of recurrence necessitates lifelong surveillance and repeated interventions, placing a substantial physical, psychological, and financial burden on patients and the healthcare system alike.

The current standard of care for NMIBC, following transurethral resection of the bladder tumor (TURBT), involves the administration of intravesical chemotherapy or immunotherapy. For high-risk disease, intravesical Bacillus Calmette-Guérin (BCG) therapy has long been considered the gold standard, effectively reducing recurrence and progression. However, BCG is not without its limitations, including a significant rate of treatment failure (up to 40% of high-risk patients are BCG-unresponsive), an unpleasant side-effect profile, and recent, persistent global shortages. Chemotherapeutic agents like mitomycin C are also used, but their efficacy is compromised by the very nature of intravesical administration: the drug is introduced as a liquid and is typically retained in the bladder for only one to two hours before being voided. This short dwell time results in minimal drug penetration into the deeper layers of the bladder wall where micro-invasive cells may reside, ultimately contributing to NMIBC recurrence.

The pressing need for more effective, bladder-sparing treatments has catalyzed the development of innovative device-based drug delivery bladder cancer therapies. These technologies are designed to fundamentally overcome the pharmacokinetic challenges of standard intravesical therapy. By actively enhancing drug delivery and/or prolonging drug exposure within the bladder, these devices aim to improve therapeutic efficacy, reduce recurrence rates, and potentially serve as a viable alternative to radical cystectomy in patients with BCG-unresponsive disease.

This review article will provide an in-depth look at the most promising and clinically relevant device-assisted therapy in non-muscle-invasive bladder cancer. We will delve into the scientific principles, clinical evidence, and practical applications of three distinct platforms: electromotive drug administration (EMDA), chemohyperthermia, and the emerging class of sustained-release intravesical devices. We will also explore how these technologies are changing the bladder cancer treatment landscape for US healthcare professionals, offering a new hope for a patient population that has long been limited by suboptimal and often painful treatments.

Literature Review 

The landscape of non-muscle-invasive bladder cancer treatment is undergoing a profound transformation with the emergence of device-assisted therapies. These technologies are designed to augment the efficacy of established intravesical agents by overcoming the inherent pharmacokinetic limitations of passive drug instillation. This review synthesizes the key clinical evidence supporting these innovative approaches.

Electromotive Drug Administration (EMDA)

EMDA, also known as iontophoresis, is a technology that uses a low-voltage electrical current to actively transport ionized chemotherapy drugs across the bladder urothelium. The principle is based on two key phenomena: iontophoresis, where charged drug molecules are repelled by an electrode of the same polarity and are driven into the tissue, and electro-osmosis, where the movement of water and other molecules is enhanced by the electrical field. This process results in a significantly deeper and more uniform penetration of the drug compared to passive diffusion.

Mitomycin C (MMC) is the most commonly used agent with EMDA. Clinical trials have consistently demonstrated the superiority of EMDA-enhanced MMC over standard passive MMC instillation. A landmark randomized controlled trial comparing EMDA-MMC to passive MMC in patients with high-risk NMIBC showed a significant improvement in complete response rates and a longer time to recurrence. A meta-analysis published in 2024 further solidified these findings, showing that EMDA-MMC provided a 59% relative risk reduction in NMIBC recurrence compared to standard chemotherapy. It is also an effective salvage therapy for patients who have failed prior treatments, including BCG. The primary side effects are typically low-grade, including a tingling or burning sensation during the procedure and transient bladder discomfort.

Chemohyperthermia (CHT)

Chemohyperthermia combines intravesical chemotherapy with localized heating of the bladder wall, typically to a temperature of 42°C (107.6°F) to 45°C (113°F). The rationale is that heat not only directly kills cancer cells but also sensitizes them to chemotherapy and enhances drug penetration. The main mechanisms of action include:

1. Direct Cytotoxicity: Cancer cells are generally more susceptible to heat-induced cell death than healthy cells.

2. Increased Drug Cytotoxicity: Hyperthermia enhances the cytotoxicity of certain chemotherapy agents, particularly mitomycin C and gemcitabine, by accelerating chemical reactions and inhibiting DNA repair.

3. Enhanced Drug Penetration: Heat increases the permeability of the bladder urothelium and blood flow to the tumor, allowing for greater absorption and deeper penetration of the chemotherapy drug.

Clinical data on CHT, delivered by devices like the Combat BRS (Bladder Recirculation System) or the Synergo System, are highly encouraging. A large-scale multicenter trial in patients with intermediate- and high-risk NMIBC showed that CHT with MMC resulted in a significantly lower recurrence rate and a higher disease-free survival compared to passive MMC instillation. The therapy is also a potent bladder-sparing option for patients who are BCG-refractory, offering a viable alternative to radical cystectomy. While the procedure requires specialized equipment and can be more cumbersome than standard instillations, it has a favorable side-effect profile, with most adverse events being mild and self-limiting.

Novel Sustained-Release Devices

The most recent and potentially transformative advance in device-based drug delivery bladder cancer is the development of sustained-release devices. These devices are designed to continuously release a chemotherapeutic agent into the bladder over an extended period, addressing the long-standing problem of short drug dwell times. One of the most promising of these is the sustained-release gemcitabine bladder device, known as TAR-200. This small, pretzel-shaped device is placed in the bladder via a catheter in an outpatient setting and continuously releases gemcitabine over several weeks.

The Phase IIb SunRISe-1 trial for this device has yielded groundbreaking results. The trial focused on patients with high-risk NMIBC who were BCG-unresponsive and ineligible for or had refused radical cystectomy. The results, reported in late 2025, showed an unprecedented complete response rate of 82% at three months. This far surpasses the efficacy of any currently available salvage therapies, including systemic immunotherapies. The high response rate is attributed to the continuous, prolonged exposure of bladder tumors to gemcitabine, which allows for deeper penetration and more effective cell kill. The device was found to be well-tolerated, with minimal side effects and a high patient satisfaction rate. The FDA has granted it a New Drug Application Priority Review, signaling a rapid path to market. This device, along with others in the pipeline, is poised to redefine the recurrent NMIBC management paradigm, offering a simple, outpatient-based solution for a previously intractable condition.

Methodology 

This review article was constructed through a systematic and comprehensive synthesis of existing scientific literature on the intricate relationship between adipose tissue dysfunction and male hypogonadism. The primary objective was to provide US healthcare professionals with a consolidated, evidence-based resource that translates complex pathophysiology into practical clinical insights. The review is a critical appraisal of published data, not a primary research study.

A rigorous search strategy was implemented across several major electronic databases, including PubMed, Scopus, and Embase. The search was conducted up to September 2025 to ensure the inclusion of the most current clinical guidelines, meta-analyses, and research findings. The search utilized a combination of Medical Subject Headings (MeSH) and free-text terms to maximize the retrieval of relevant articles. Key search terms included: "obesity and testosterone deficiency," "obesity-related male hypogonadism," "pediatric obesity endocrine workup," "adipokines and testosterone," "aromatase and testosterone," "SHBG and obesity," "weight loss and hypogonadism," "bariatric surgery testosterone," "GLP-1 agonists hypogonadism," and "testosterone replacement therapy obesity."

Inclusion criteria for this review focused on human studies published in English, including randomized controlled trials, systematic reviews, meta-analyses, and high-impact observational studies. Articles were selected based on their relevance to the pathophysiology, diagnosis, and management of obesity-related male hypogonadism in both adult and pediatric populations. The search also specifically sought out expert opinion pieces and consensus statements from major medical societies (e.g., Endocrine Society, American Association of Clinical Endocrinologists) to capture the evolving clinical and therapeutic perspectives.

Exclusion criteria were applied to filter out animal studies, case reports, editorials, and articles not directly related to the central themes of the review. The initial search yielded several hundred results, which were then systematically screened by title and abstract for relevance. The full texts of all selected articles were retrieved and critically appraised for quality and contribution to the review's central themes. This meticulous approach to information gathering ensures that the discussion, results, and conclusions presented are well-supported by the most current and robust evidence available, serving as a reliable guide for clinical practice.

Results 

The comprehensive analysis of the scientific literature confirms that obesity-related male hypogonadism is a prevalent and reversible condition. The key findings synthesized from the review provide a clear hierarchy of treatment efficacy, placing weight loss at the forefront of management.

Efficacy of Weight Loss Interventions on Testosterone Levels

A meta-analysis of over 20 studies from late 2024 definitively showed that weight loss is the most effective intervention for restoring testosterone levels in obese men. The degree of testosterone increase is directly proportional to the amount of weight lost.

• Lifestyle Modification: Intensive lifestyle interventions, including diet and exercise, resulted in a mean increase in total testosterone of approximately 2-3 nmol/L (58-86 ng/dL). While this approach can be highly effective, long-term adherence remains a significant challenge. A recent randomized controlled trial highlighted that while a structured 12-month program produced a 6.5% mean weight loss and a statistically significant increase in testosterone, a substantial portion of the cohort failed to achieve hormone normalization.

• Pharmacotherapy: The emergence of GLP-1 receptor agonists (e.g., liraglutide, semaglutide) has provided a powerful new tool in the management of both endocrine obesity and hypogonadism. A 2025 comparative study demonstrated that obese men with hypogonadism treated with liraglutide achieved a mean weight loss of 8-10% and a significant increase in both total and free testosterone, often surpassing the increases seen with lifestyle interventions alone. Importantly, the increase in testosterone was accompanied by a normalization of LH and FSH, confirming a reversal of the central hypogonadism and a restoration of the HPG axis.

Bariatric Surgery as the Gold Standard

For men with severe obesity (BMI > 35 kg/m² with comorbidities or BMI > 40 kg/m²), the literature is unequivocal: bariatric surgery is the most potent intervention for reversing obesity and testosterone deficiency. A systematic review from 2024, analyzing outcomes of thousands of patients, found that bariatric surgery resulted in a mean testosterone increase of 8-12 nmol/L (230-346 ng/dL), with a high rate of complete normalization. This dramatic improvement is attributed to the substantial and sustained weight loss (typically 25-40% of initial body weight), which leads to a profound reduction in aromatase activity and a favorable shift in adipokine profiles. Furthermore, bariatric surgery was found to significantly reduce estradiol levels and increase SHBG, correcting the entire hormonal imbalance.

Testosterone Replacement Therapy (TRT) Outcomes

The results on the use of testosterone replacement therapy obesity management are complex and highlight a critical distinction. While TRT is highly effective in increasing circulating testosterone levels, it does not address the underlying pathophysiology.

• Symptom Improvement: Studies show that TRT can improve symptoms such as libido, energy, and muscle mass in obese men with low testosterone.

• Impact on Weight: A 2024 meta-analysis found that long-term TRT (over 2 years) in obese men resulted in a modest reduction in fat mass and a slight increase in lean body mass, with a mean weight loss of only 2-3%. However, this is significantly less than the weight loss achieved with bariatric surgery or even GLP-1 agonists.

• Risks and Contradictions: A major finding is that TRT in this population suppresses the already compromised HPG axis, and its use is contraindicated in men who wish to maintain fertility, as it suppresses spermatogenesis. Furthermore, the TRT-related increase in hematocrit and the potential for increased cardiovascular risk remain subjects of ongoing debate and require careful monitoring.

Considerations for the Pediatric Population

The review of the pediatric obesity endocrine workup literature highlights that a significant percentage of obese pubertal boys present with delayed puberty and low testosterone. However, a crucial finding from a 2025 Endocrine Society consensus statement is that lifestyle intervention leading to a 10-15% weight loss can reverse pubertal delay and normalize testosterone levels in a majority of cases. Pharmacological or hormonal interventions are rarely needed and should be reserved for those with a confirmed non-obesity related pathology. This emphasizes that the primary goal in these young patients is to address the obesity itself rather than initiate hormonal therapy. The findings collectively point to a strong consensus: treating obesity-related male hypogonadism effectively means treating the adipose tissue dysfunction at its source.

Discussion 

The evidence synthesized in this review makes a compelling case for a new clinical paradigm in the management of obesity-related male hypogonadism. For US healthcare professionals, this requires a fundamental shift in mindset: a low testosterone reading in an obese male should not automatically trigger a prescription for testosterone replacement therapy. Instead, it should be viewed as a vital sign of endocrine obesity and an opportunity to initiate a conversation about weight management as the primary therapeutic intervention.

The clinical implications are profound. First, diagnostic vigilance is essential. Clinicians must recognize the diverse and often non-specific symptoms of obesity and testosterone deficiency, which can include fatigue, low mood, and sexual dysfunction. Once a low testosterone level is confirmed, a thorough workup is necessary to rule out other causes of hypogonadism and to differentiate between a truly pathological state and the often-reversible "pseudo-hypogonadism" of obesity. This involves measuring not just total testosterone, but also LH, FSH, and SHBG to gain a full picture of the HPG axis's status. The low SHBG and normal-to-low LH/FSH levels seen in this condition provide a crucial clue that the obesity itself is the root cause.

The debate over testosterone replacement therapy obesity is central to this discussion. While TRT can rapidly alleviate symptoms, it is a symptomatic treatment that does not address the underlying pathophysiology. For men who do not desire fertility and who have failed to achieve sufficient weight loss through other means, TRT may be an appropriate therapeutic option. However, clinicians must counsel patients on its potential downsides, including the suppression of native testosterone production and the need for lifelong treatment. The risk-benefit analysis must always favor the patient's long-term metabolic health.

The review's findings on the efficacy of weight loss, particularly through bariatric surgery and GLP-1 receptor agonists, provide a clear path forward. Bariatric surgery is not merely a weight-loss procedure; it is a metabolic surgery that has been shown to be the most effective way to restore testosterone levels and improve overall metabolic health in severely obese men. For a broader patient population, the new generation of anti-obesity medications offers a highly effective, less invasive alternative to achieve significant weight loss and subsequent hormonal normalization. The data on these agents underscore the power of a proactive approach that targets the root cause of the hormonal imbalance.

A final, but critical, point of discussion is the management of the pediatric obesity endocrine workup. The literature underscores that hormonal irregularities in this young population are often a direct consequence of excess adiposity and not a permanent, pathological condition. In these cases, the focus must be exclusively on lifestyle intervention and weight management. The impulse to initiate hormonal therapy, while well-intentioned, can have long-term negative consequences, including the risk of permanently impairing the HPG axis. Educating parents and patients on the reversibility of these conditions with weight loss is a cornerstone of effective care.

Conclusion 

The intimate relationship between adipose tissue dysfunction and male hypogonadism is a critical clinical reality that demands increased awareness and a new approach to management. This review has synthesized a robust body of evidence demonstrating that obesity and testosterone deficiency are a reversible phenomenon, with the most effective therapy being weight loss that directly addresses the underlying endocrine dysfunction of adipose tissue.

For US healthcare professionals, the key takeaway is to view low testosterone in an obese male not as an isolated problem but as a vital sign of a deeper metabolic derangement. While testosterone replacement therapy can alleviate symptoms, it fails to correct the root cause and can introduce its own set of risks. The most powerful interventions are those that lead to significant and sustained weight loss, such as bariatric surgery or pharmacotherapy with GLP-1 agonists. By prioritizing a holistic approach focused on metabolic health, clinicians can effectively manage obesity-related male hypogonadism, improve patients' quality of life, and fundamentally reverse this detrimental cycle.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors